General Information of Drug (ID: DM3PEUN)

Drug Name
Dihydropyrido pyrazinone compound 3 Drug Info
Synonyms PMID26924192-Compound-60
Cross-matching ID
TTD Drug ID
DM3PEUN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Drug(s) Targeting Polo-like kinase 1 (PLK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Rigosertib DMOSTXF Myelodysplastic syndrome 2A37 Phase 3 [2]
Volasertib DMOFH1M Acute myeloid leukaemia 2A60 Phase 3 [3]
PCM-075 DMYFRTB Acute myeloid leukaemia 2A60 Phase 2 [4]
BI 2536 DMJSADP Acute myeloid leukaemia 2A60 Phase 2 [5]
MK-1496 DME1ZAH Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
GSK461364 DM0P729 Non-hodgkin lymphoma 2B33.5 Phase 1 [5]
TAK-960 DMN4OGH Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
CYC140 DMC6PKJ Acute myeloid leukaemia 2A60 Phase 1 [8]
Dihydropyrido pyrazinone compound 2 DMOTG2Y N. A. N. A. Patented [1]
HMN-214 DMH4ANG Pancreatic cancer 2C10 Discontinued in Phase 1 [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Polo-like kinase 1 (PLK1) TTIYVQP PLK1_HUMAN Inhibitor [1]

References

1 BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
2 Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168).
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
6 J Clin Oncol 29: 2011 (suppl; abstr 3012).
7 TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther. 2012 Mar;11(3):700-9.
8 Clinical pipeline report, company report or official report of Cyclacel Pharmaceuticals.